Search

Your search keyword '"Lise Willems"' showing total 107 results

Search Constraints

Start Over You searched for: Author "Lise Willems" Remove constraint Author: "Lise Willems" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
107 results on '"Lise Willems"'

Search Results

1. Exposure toxicity of venetoclax in acute myeloid leukemia patients in the real-life setting: impact of high exposure on delayed neutropenia

2. Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation

3. VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation

4. S162: LOSS OF HEMATOPOIETIC PROGENITORS HETEROGENEITY IS AN ADVERSE PROGNOSTIC FACTOR IN MYELODYSPLASTIC SYNDROMES

5. S232: EFFICACY AND TOXICITY OF CAR-T CELLS IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS, A NEW REFERENCE: THE FRENCH EXPERIENCE OF THE NATIONAL LOC NETWORK

6. Hematopoietic differentiation is characterized by a transient peak of entropy at a single-cell level

7. Antimicrobial stewardship in high-risk febrile neutropenia patients

8. Subcutaneous azacitidine maintenance in transplantineligible patients with acute myeloid leukemia: a single-center retrospective study

9. Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis

10. Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy

11. Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era

12. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents

13. Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients

14. Skin Microvascular Thrombosis in Fusarium Infection in Two Early Biopsied Cases

15. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia

16. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody

17. Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)

18. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network

19. Supplementary Figures 1 - 4 from Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

20. Data from Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

21. Supplementary Figure Legend, Table 1 from Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

23. Pharmaceutical cancer care for haematology patients on oral anticancer drugs: Findings from an economic, clinical and organisational analysis

24. Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study

25. Successful nelarabine and venetoclax treatment of a relapsed/refractory mediastinal myeloid sarcoma with clonal TCR rearrangement

26. Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

27. Management of Gastro-Intestinal Toxicity of the Pi3 Kinase Inhibitor: Optimizing Future Dosing Strategies

28. Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

29. DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation

30. Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

31. Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases

32. Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia

33. Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma

34. VEXAS Syndrome Is Characterized by Blood and Tissues Inflammasome Pathway Activation and Monocyte Dysregulation

35. Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy

36. Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 inpatients with chronic lymphocytic leukemia

37. Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network

38. Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients

40. Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study

41. The fraction of CD117/c‐KIT‐expressing erythroid precursors predicts ESA response in low‐risk myelodysplastic syndromes

42. High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah’s Witnesses patients: a feasible option in the age of hematopoietic growth factors

43. CAR‐T CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL): THE EXPERIENCE OF THE FRENCH NETWORK FOR OCULO‐CEREBRAL LYMPHOMAS (LOC)

44. Hematopoietic differentiation is characterized by a transient peak of entropy at a single cell level

45. Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network

46. Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis

47. Eprenetapopt Plus Azacitidine in

48. Inflammatory myopathies associated with myelodysplastic syndromes: A French multicenter case control study and literature review

49. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO)

50. Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study

Catalog

Books, media, physical & digital resources